A survey shows at least one third of the total HIV patients in sub-Saharan Africa die or discontinue their HIV medication within two years of taking the medicine due to distant clinics.

U.S. researchers also found out that some patients stopped the treatment due to financial problems

Uganda has opened its first pharmaceutical factory on Monday, to make drugs used to fight HIV/AIDS. Authorities say they will make the medicine, specifically to offer to citizens at discounted prices. The Kampala-based Quality Chemicals Limited is expected to start producing anti-retroviral HIV drugs (ARVs) and anti-malaria drugs as soon as January.

The $38 million factory will receive its ingredients from Indian giant drugmaker Cipla. The director of the factory Emmanuel Katongole, said "Our target is that everybody who requires ARVs will be getting them

Ahead of a major HIV-fundraising meeting in Berlin, the United Nations Children's Fund (UNICEF) on Tuesday called for more AIDS prevention and medication programmes aimed at young people.

Only 15 percent of the children who need anti-retroviral drugs are receiving them, UNICEF said adding that 330,000 children are dying every year of AIDS

In an effort to provide free HIV/AIDS care -- including lifesaving antiretroviral treatment (ART) -- to people living with advanced AIDS Thai authorities will open their first free AIDS treatment clinic. The facility located in the region near Lop Buri 75 miles north of Bangkok will extend life and bring hope for people living with HIV/AIDS.

The clinic, which will be known as the 'Wat Phrabatnampo-Center of Hope' is located on the grounds of Wat Phrabatnampo -- Thailand's world-renowned AIDS temple. Since 1992 the temple has been the site for thousands of Thais living with AIDS to receive hospice care

Former President Bill Clinton's Foundation has reached an agreement with two drug companies to offer HIV/AIDS drugs at lower prices to 66 developing nations in Africa, Asia, the Caribbean and Latin America.

The deal, brokered by the Clinton Foundation's Procurement Consortium, will provide 16 different formulas of anti-retroviral drugs (ARVs) to patients who develop a resistance to a first-line of medication. The deal will cut prices by 25 percent in low-income countries and 50 percent in middle-income countries